1.  **What do we already know about this topic?**

2.  Access to essential medicines is one of the topical issues in low- and middle-income countries (LMICs) like Nepal. There have been reports about the unavailability and unaffordability of essential medicines in many LMICs, which can be a challenge to the health care system of such countries.

3.  **How does your research contribute to the field?**

4.  It generates evidence on the availability, cost, and affordability of essential medicines to treat noncommunicable diseases in developing countries like Nepal. This can be reference cost to Nepal and other LMICs with similar health care system.

5.  **What are your research's implications toward theory, practice, or policy?**

6.  The research will be useful for policy makers, funding agencies, donors, and other stakeholders to plan funding priorities and decisions for much awaited Universal Health Coverage in Nepal; it can also be important to other similar countries. Nepal is planning social health insurance; therefore, the data on cost and affordability will be of topical interest and can influence on its policy.

Background {#section1-0046958019887572}
==========

Nepal is a small landlocked country (147 181 km^2^) of 29 million people where almost 2 out of 5 live below the poverty line as determined by the multidimensional poverty index.^[@bibr1-0046958019887572]^ While contagious or communicable diseases have been the focus of treatment efforts for many years like many low- and middle-income countries (LMICs), but recently, the rising burden of noncommunicable diseases (NCDs), such as cardiovascular diseases (CVDs), cancer, chronic respiratory diseases, and diabetes, has created substantial attention.^[@bibr2-0046958019887572][@bibr3-0046958019887572]-[@bibr4-0046958019887572]^ This growing burden of NCDs, along with the preexisting burden of communicable diseases, has challenged the health care systems in Nepal, as it has in other LMICs. The mortality and morbidity due to NCDs are increasing globally but the rate of mortality and morbidity is higher in the South East Asian region (which includes Nepal) than in other regions (excluding Africa).^[@bibr2-0046958019887572]^ With an estimated 39% of total disease burden and almost half of the total death attributed to NCDs (22% CVDs, 7% cancers, 5% respiratory diseases, and 1.7% diabetes related deaths out of all deaths), Nepal face huge NCD-related challenges.^[@bibr5-0046958019887572]^ Although there are many measures to prevent these diseases, once diagnosed the main treatment modality is often medication. Hence, the need for NCD medicines will increase and countries like Nepal need to plan to make these medicines available and affordable for the population. This will have implications for the budgets of both governments and the wider public, especially in LMICs. The cost of medicines is a major component of the health budget of any country. Most (50%-90%) of the direct medical costs (excluding salaries for health care workers) are for medicines.^[@bibr6-0046958019887572],[@bibr7-0046958019887572]^

Developing and adhering to the essential medicine list (EML) is one of the most efficient ways to ensure availability and affordability of medicines for the population.^[@bibr8-0046958019887572],[@bibr9-0046958019887572]^ The essential medicine list is the basis of the national medicine policy in many countries.^[@bibr8-0046958019887572],[@bibr9-0046958019887572]^ It comprises a list of medicines which satisfy the health care needs of most of the population. These medicines should, therefore, be available at all times in adequate quantity and in appropriate dosage forms, at a price the community can afford.^[@bibr9-0046958019887572]^ We previously compared the World Health Organization (WHO) EML 2011^[@bibr9-0046958019887572]^ and Nepal's EML 2011^[@bibr10-0046958019887572]^ for the inclusion of NCD medicines. Of 28 noncancer NCD medicines in the WHO EML, 23 were present in the Nepalese EML. Five medicines were not present in Nepal's EML but most of them had equivalent medicines (eg, glipizide was in the Nepalese EML in lieu of gliclazide in WHO EML). The inclusion of NCD medicines in Nepal's EML may not, however, reflect the actual availability and affordability in the country or may not be best indicator to represent if people in Nepal have access to certain medicines. Access to essential NCD medicines is a concern in Nepal.^[@bibr11-0046958019887572]^ The Government of Nepal, through the Ministry of Health and Population, used to provide 70 essential medicines (during the period when this survey was carried out), including those for NCDs, at public health care facilities free of cost. However, the universal coverage of these free medicines has been questioned, as some studies reported that free medicines were not available most of the time in health care facilities and there were many administrative steps to get the medicines for free.^[@bibr12-0046958019887572][@bibr13-0046958019887572]-[@bibr14-0046958019887572]^ Until the universal health coverage becomes reality, it is very important to determine whether medicines are actually available to the people in Nepal; it is also very important to determine whether there is any price variation between same medicines within different geographic area in Nepal. With data about the price of medicines, the concerned stakeholders (funding bodies, health policy bodies, and so on) can determine whether people in Nepal can afford the treatment for NCDs. Like other LMICs, Nepal needs to use its limited health care resources efficiently to care for people with NCDs. It requires a sustainable patient-centered and community-based program at the level of primary health care (PHC). Although there are not standard treatment practice guidelines for chronic diseases at the primary care level, there is need for such guiding documents. WHO has developed a framework known as the "Package of essential non-communicable (PEN) disease interventions for PHC in low resource settings."^[@bibr15-0046958019887572]^ We developed a list of medicines required to treat NCDs based on the WHO EML,^[@bibr9-0046958019887572]^ Nepal EML,^[@bibr10-0046958019887572]^ PEN recommendations,^[@bibr15-0046958019887572]^ and current treatment practice in Nepal. With this background, we aimed to investigate the availability, price, and affordability of NCD medicines in Nepal. We hope this research will help to gather information about whether people in Nepal can afford treatment for NCDs, and we also believe the information can be used by different stakeholders to budget medicine price for NCDs.

Methods {#section2-0046958019887572}
=======

We followed standard methods recommended by WHO and Health Action International (HAI) to conduct and report our survey.^[@bibr16-0046958019887572]^ We registered the protocol of this survey with WHO/HAI Medicine Survey Database.

Survey Areas {#section3-0046958019887572}
------------

We collected data on the availability and price of selected NCD medicines from 6 survey areas in Nepal in March 2015. We surveyed 5 public and 5 private medicine outlets in each of the 6 areas for availability and price. Medicines in Nepal are sold either in private pharmacies (private outlets) or distributed free at government health facilities (public outlets) such as subhealth posts, health posts, primary health care centers, and government hospitals. The medicines in public outlets are generally not distributed via their own pharmacies; pharmacies inside the hospital are run privately. Free medicines in public hospitals are stored in a separate place (commonly called medical store) from where medicines are distributed to poor patients who satisfy requisite administrative requirements; usually, the decision of providing medicines for free should be approved by hospital superintendent or higher authority. Their decisions are usually based on the recommendation letter from the local government stating the patients cannot afford the treatment.

We did not collect price data from public medicine outlets because medicines in the list are generally distributed free of charge. The WHO/HAI methodology recommends selecting the capital city and at least 5 other survey areas based on the location and population. Therefore, we selected 6 cities for our survey: Kathmandu (capital city); Biratnagar (Eastern Development Region); Janakpur (Central Development Region); Pokhara (Western Development Region); Nepalgunj (Mid-Western Development Region); and Dhangadi (Far-Western Development Region). The selected survey areas represent the capital city (Kathmandu) and the most populous cities from each of the 5 administrative divisions of Nepal ([Figure 1](#fig1-0046958019887572){ref-type="fig"}).

![Map of survey areas in Nepal.](10.1177_0046958019887572-fig1){#fig1-0046958019887572}

Data Collection {#section4-0046958019887572}
---------------

S.K. trained 6 area supervisors, 6 data collectors, and 2 data entry personnel over 3 days in the knowledge and skills required to conduct the survey in accordance with the WHO/HAI method.^[@bibr17-0046958019887572]^ We used a standardized data collection form to ensure data reliability and consistency. We also conducted a localized pilot study in Baglung (not a part of the main survey) during the training to verify the feasibility of the survey.

We collected data on the availability and patient prices (lowest priced generic) of specified medicines at the selected public facilities and private retail pharmacies. Area supervisors made appointments with responsible people at the survey outlets before the formal data collection to ensure survey efficiency. Subsequently, data collectors surveyed each outlet. Area supervisors met with them at the end of each day to check completed data collection forms and ensure that the data were complete, consistent, and legible. The data collection was completed within 2 weeks.

Data Entry and Analysis {#section5-0046958019887572}
-----------------------

We used the workbook developed by WHO/HAI for data entry.^[@bibr16-0046958019887572]^ All data were entered twice by 2 people, followed by software verification and validation through "double entry" and "data checker" functions to identify any data entry errors. Furthermore, we used codes to identify the public health care facilities and private pharmacies, instead of the actual names, to maintain their anonymity.

The study end points focused on 3 measures: medicine availability, price, and affordability. Availability was defined as the proportion of pharmacies in which the medicines were available at the time of the survey. We determined the availability of any type of generic medicines in public facilities and private pharmacies. Prices were presented as Nepalese Rupees (NPR). We estimated affordability by comparing the total cost of a medicine for a standard course of 1 month's treatment to the daily wage of the lowest paid unskilled government worker, which was 265 NPR per day at the time of the survey.^[@bibr1-0046958019887572]^

Medicines Surveyed {#section6-0046958019887572}
------------------

We compiled a list of 60 NCD medicines ([Table 2](#table2-0046958019887572){ref-type="table"}) based on the WHO recommended Package of Essential NCD (PEN),^[@bibr15-0046958019887572]^ WHO EML,^[@bibr9-0046958019887572]^ Nepal EML,^[@bibr10-0046958019887572]^ and treatment practice in Nepal. This list included basic medicines required to provide primary health care for CVDs, diabetes, and chronic respiratory disease and medicines used for palliative care in cancer.

Results {#section7-0046958019887572}
=======

Availability {#section8-0046958019887572}
------------

The availability of medicines was higher (78%) in private outlets than public outlets (60%). There was very good availability (more than 90%) for 13 out of 34 NCD medicines in private outlets but only 8 medicines had more than 90% availability in public outlets. Most of these highly available medicines were for treating CVDs. Senna was not available in any of the outlets. Oxygen was not available in the private sector and had poor availability in the public sector. Overall, private outlets had better availability of medicines required for treating NCDs in primary care than public outlets ([Table 1](#table1-0046958019887572){ref-type="table"}). There was no significant difference (*P* \< .05) in the availability of medicines across the 6 survey areas in our study.

###### 

Availability of the Core List of Medicines Required for Implementing Essential Noncommunicable Disease Interventions in Primary Care (World Health Organization).

![](10.1177_0046958019887572-table1)

  Medicines (any dose or dosage form unless indicated)    Public sector, N = 30   Private sector, N = 30
  ------------------------------------------------------- ----------------------- ------------------------
  Thiazide diuretic                                       67%                     100%
  Calcium channel blocker (long acting)                   73%                     100%
  Beta-blocker                                            67%                     100%
  Angiotensin converting enzyme inhibitor (long acting)   53%                     100%
  Statin                                                  67%                     100%
  Insulin                                                 20%                     47%
  Metformin                                               60%                     100%
  Glibenclamide                                           73%                     100%
  Isosorbide dinitrate                                    27%                     97%
  Glyceryl trinitrate                                     27%                     100%
  Furosemide                                              67%                     93%
  Spironolactone                                          67%                     97%
  Salbutamol (tab/inhaler/rotacap)                        100%                    100%
  Prednisolone                                            100%                    100%
  Beclometasone (inhaler)                                 0%                      87%
  Aspirin                                                 100%                    93%
  Paracetamol                                             100%                    100%
  Ibuprofen                                               100%                    100%
  Codeine                                                 80%                     73%
  Morphine                                                20%                     10%
  Penicillin                                              80%                     60%
  Erythromycin                                            63%                     80%
  Amoxicillin                                             100%                    100%
  Hydrocortisone                                          53%                     67%
  Epinephrine                                             53%                     73%
  Heparin                                                 20%                     10%
  Diazepam                                                40%                     63%
  Magnesium sulfate                                       20%                     40%
  Promethazine                                            60%                     80%
  Senna                                                   0%                      0%
  Dextrose infusion                                       100%                    83%
  Glucose injectable solution                             50%                     60%
  Sodium chloride infusion                                100%                    73%
  Oxygen                                                  20%                     0%

Price of Medicines {#section9-0046958019887572}
==================

The price of selected NCD medicines is presented as the median price in Nepalese rupees (NPR, [Table 2](#table2-0046958019887572){ref-type="table"}). Two medicines (senna and oxygen) were excluded from the price analysis because they were not available in private outlets. Furosemide tablet was the cheapest (NPR 0.6/10 tablets) and streptokinase injection was the most expensive (NPR 2200/vial). There was no significant variation (*P* \< .05) in the price of medicines across the 6 survey areas. Most of the surveyed medicines (especially those for blood pressure, diabetes mellitus, and asthma) cost less than NPR 210 for 10 dose units.

###### 

Median Price of Lowest Price Generics of Selected Noncommunicable Disease Medicines in Private Outlets by Dose, Strength, and Units.

![](10.1177_0046958019887572-table2)

  Medicine                                                              Median price (IQR) in Nepalese rupees (NPR)   *P* value                             
  --------------------------------------------------------------------- --------------------------------------------- ------------------ ------------------ ------------------------------------------------------------
  Aminophylline (100 mg cap/tablet), 10 units                           15 (14-16)                                    15 (14-16)         15 (14-16)         1.000
  Amlodipine (5 mg, cap/tablet), 10 units                               31 (30-32)                                    31 (30-32)         31 (30-32)         .914
  Amlodipine (10 mg, cap/tablet), 10 units                              55 (54-58)                                    55 (55-58)         55 (55-58)         .872
  Amoxicillin (500 mg, cap/tablet), 10 units                            110 (110-112)                                 110 (110-122)      110 (110-119)      .589
  Aspirin (100 mg, cap/tablet), 10 units                                61 (60-62)                                    61 (60-63)         61 (60-62.75)      .829
  Aspirin (50 mg, cap/tablet), 28 units                                 52 (47-53)                                    49 (48-52)         49 (48-52.75)      .787
  Aspirin (75 mg, cap/tablet), 10 units                                 80 (78-82)                                    80 (80-82)         80 (80-82)         .516
  Atorvastatin (5 mg, cap/tablet), 10 units                             66 (62-70)                                    66 (65-70)         66 (65-70)         .516
  Atorvastatin (10 mg, cap/tablet), 10 units                            86 (85-90)                                    88 (86-90)         88 (86-90)         .481
  Atorvastatin (20 mg, cap/tablet), 10 units                            160 (160-175)                                 160 (160-170)      160 (160-173.75)   .872
  Beclomethasone inhaler (0.05 mg/dose, inhaler), 1 unit                180 (180-185)                                 184 (180-185)      184 (180-185)      .448
  Benzathine benzylpenicillin (2.4 M IU, vial), 1 unit                  160 (160-160)                                 160 (160-170)      160 (160-170)      .552
  Budesonide (200 µg/dose, inhaler), 1 unit                             208 (206-215)                                 210 (208-210)      210 (208-213.75)   .627
  Codeine (30 mg, cap/tablet), 10 units                                 90 (90-90)                                    88 (88-90)         89 (88-90)         .074
  Diazepam (5 mg, cap/tablet), 10 units                                 65 (65-66)                                    65 (65-68)         65 (65-67.5)       .872
  Digoxin (250 µg, cap/tablet), 10 units                                124 (122-125)                                 122 (120-124)      123 (120-124.75)   .552
  Digoxin injection (250 µg/mL, 2 mL), ampoule, 1 unit                  40 (40-40)                                    45 (45-48)         45 (44.25-48)      .049[\*](#table-fn2-0046958019887572){ref-type="table-fn"}
  Enalapril (2.5 mg, cap/tablet), 10 units                              31 (30-32)                                    31 (28-35)         31 (28-34.25)      .957
  Enalapril (5 mg, cap/tablet), 10 units                                44 (44-45)                                    44 (40-45)         44 (40.5-45)       1.000
  Enalapril (10 mg, cap/tablet), 10 units                               74 (72-74)                                    75 (74-76)         74 (74-76)         .122
  Epinephrine (100 µg/ mL, 10 mL), ampoule, 1 unit                      12 (12-14)                                    14 (12-15)         13 (12-14.75)      .589
  Erythromycin (250 mg, cap/tablet), 10 units                           145 (140-145)                                 145 (140-150)      145 (140-150)      .914
  Furosemide (40 mg, cap/tablet), 10 units                              6 (6-6)                                       6 (6-6)            6 (6-6)            1.000
  Furosemide (10 mg/ mL, 2 mL) ampoule, 1 unit                          7 (7-7)                                       7 (7-7)            7 (7-7)            1.000
  Glibenclamide (2.5 mg, cap/tablet), 10 units                          8 (8-8)                                       8 (8-10)           8 (8-10)           .516
  Glibenclamide (5 mg, cap/tablet), 10 units                            15 (14-15)                                    15 (14-15)         15 (14-15)         .914
  Glibenclamide (10 mg, cap/tablet), 10 units                           25 (25-25)                                    25 (24-25)         25 (24-25)         .448
  Glucose injection solution (0.05%) bottle, 1 unit                     90 (85-90)                                    88 (85-88)         88 (85-90)         .589
  Glyceryl trinitrate (500 µg, cap/tablet), 10 units                    160 (150-160)                                 155 (155-160)      155 (151.25-160)   .787
  Hydrochlorthiazide (12.5 mg, cap/tablet), 10 units                    14 (14-15)                                    15 (14-16)         15 (14-16)         .074
  Hydrochlorthiazide (25 mg, cap/tablet), 10 units                      24 (22-25)                                    25 (24-25)         25 (22.5-25)       .385
  Hydrochlorothiazide (50 mg, cap/tablet), 10 units                     52 (48-53)                                    48 (46-50)         48 (47.25-52)      .169
  Hydrocortisone (100 g vial), 1 unit                                   55 (52-57)                                    55 (50-55)         55 (50.5-55)       .481
  Ibuprofen (400 mg, cap/tablet), 10 units                              18 (15-18)                                    18 (15-18)         18 (15-18)         .787
  Insulin (intermediate acting)---zinc 40 IU/mL (10 mL), vial, 1 unit   210 (210-210)                                 210 (210-212)      210 (210-212)      .914
  Insulin (soluble) 40 IU/ mL (10 mL), vial, 1 unit                     285 (285-285)                                 285 (285-285)      285 (285-285)      1.000
  Ipratropium bromide (20 µg/dose, inhaler), 1 unit                     230 (225-230)                                 225 (225-230)      225 (225-230)      .448
  Isoprenaline (1 mg/5 mL, vial), 1 unit                                530 (520-540)                                 525 (525-540)      525 (525-540)      .957
  Isosorbide dinitrate (5 mg, cap/tablet), 10 units                     35 (35-35)                                    35 (35-35)         35 (35-35)         .589
  Metformin (500 mg, cap/tablet), 10 units                              21 (21-22)                                    21 (21-22)         21 (21-22)         .829
  Metformin (850 mg, cap/tablet), 10 units                              30 (30-30)                                    28 (25-32)         29 (28-32)         .481
  Methyldopa (250 mg, cap/tablet), 10 units                             25 (25-25)                                    25 (24-25)         25 (24-25)         .914
  Methyldopa (500 mg cap/tablet), 10 units                              66 (65-68)                                    66 (65-68)         66 (65-68)         .706
  Metoprolol (12.5 mg, cap/tablet), 10 units                            28 (27-29)                                    27 (25-28)         27 (25-28)         .251
  Metoprolol (25 mg, cap/tablet), 10 units                              40 (40-45)                                    43 (42-44)         43 (42-44)         .589
  Metoprolol (50 mg, cap/tablet), 10 units                              50 (45-50)                                    50 (50-50)         50 (50-50)         .481
  Morpphine sulfate (30 mg, cap/tablet), 10 units                       64 (60-80)                                    65 (60-66)         65 (60-66)         1.000
  Paracetamol (500 mg, cap/tablet), 10 units                            10 (7-10)                                     10 (7-10)          10 (7-10)          .914
  Phenoxymethyl penicillin (250 mg, cap/tablet), 10 units               185 (185-190)                                 189 (185-190)      189 (185-190)      .589
  Prednisolone (5 mg, cap/tablet), 10 units                             18 (18-18)                                    18 (18-20)         18 (18-20)         .829
  Prednisolone (20 mg, cap/tablet), 10 units                            50 (50-50)                                    50 (50-50)         50 (50-50)         1.000
  Salbutamol inhaler (0.1 mg/dose, inhaler), 1 unit                     161 (160-162)                                 161 (160-164)      161 (160-164)      .516
  Salbutamol rotacap (200 µg, cap/tablet), 30 units                     15 (15-20)                                    17 (16-18)         17 (15-18)         .706
  Salbutamol tablet (2 mg, cap/tablet), 10 units                        16 (14-16)                                    16 (16-18)         16 (16-17.5)       .122
  Sodium chloride infusion (0.009500 mL bottle), 1 unit                 50 (50-50)                                    50 (50-55)         50 (50-55)         .208
  Spironolactone (25 mg, cap/tablet), 10 units                          88 (88-88)                                    88 (86-90)         88 (86-90)         .957
  Streptokinase (1500000 IU, vial), 1 unit                              2200 (2200-2200)                              2200 (2200-2200)   2200 (2200-2200)   .746
  Timolol eye drop (0.0025, eye drop), 1 unit                           75 (75-75)                                    77 (75-80)         76 (75-78)         .169
  Verapamil (40 mg, cap/tablet), 10 units                               130 (126-130)                                 125 (120-130)      126 (120-130)      .416
  Verapamil (80 mg, cap/tablet), 10 units                               188 (180-220)                                 189 (180-190)      189 (180-190)      .957

*Note.* 1 USD = approximately 110 NPR. *P* value reports any difference in median price between Kathmandu (capital city) and other 5 major cities of Nepal. *P* value (2 sided) was calculated by Mann-Whitney *U* test.

Significant at α = 0.05.

Affordability {#section10-0046958019887572}
=============

We calculated the affordability of medicines for a Nepalese person to treat selected NCD conditions: asthma, diabetes, hypertension, and hyperlipidemia. We included the price of medicines in the private sector only as some medicines are available free of charge in the public sector. Because there was the poor availability of many medicines in the public sector, we anticipated that people would purchase medicines from private outlets. For all of the NCD conditions evaluated in this study, patients would need to spend less than a day's wage to purchase medicines for 1 month of treatment ([Table 3](#table3-0046958019887572){ref-type="table"}). NCD conditions and the standard treatment to treat the condition have been adopted from WHO/HAI methods.

###### 

The Affordability of Selected NCD Medicines Based on the Number of Days' Wages Needed for the Lowest Paid Nepalese Unskilled Government Worker to Purchase Standard Treatments for Adults With Specific Conditions.

![](10.1177_0046958019887572-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Conditions and medicines         Treatment schedule      No. of medicines required/month   Unit price (NPR)   Total monthly cost NPR   Days wages to pay treatment
  -------------------------------- ----------------------- --------------------------------- ------------------ ------------------------ -----------------------------
  Asthma\                          1 inhaler per month     1                                 161                161                      0.61
  Salbutamol inhaler 100 µg/puff                                                                                                         

  Diabetes\                        1 cap/tab x 2×30 days   60                                1.5                90                       0.34
  Glibenclamide 5 mg cap/tab                                                                                                             

  Metformin 850 mg cap/tab         1 cap/tab x 2×30 days   60                                2.9                174                      0.66

  Hypertension\                    1 cap/tab x 2×30 days   60                                4.4                264                      1.00
  Enalapril 5 mg cap/tab                                                                                                                 

  Amlodipine 5 mg cap/tab          1 cap/tab x 1×30 days   30                                3.1                93                       0.35

  Hyperlipidemia\                  1 cap/tab x 1×30 days   30                                6.6                198                      0.75
  Atorvastatin 10 mg cap/tab                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#section11-0046958019887572}
==========

The WHO global action plan for the prevention and control of NCDs has set a voluntary target for LMICs to make essential NCDs medicines available (in both public and private sectors) and affordable to 80% of the population by 2025.^[@bibr18-0046958019887572]^ Our study showed the availability was suboptimal in the public (60%) sector, with better availability in the private (78%) sector. The reduced availability of public outlets might be due to inadequate government funding, the inability to forecast medicine needs accurately, and an inefficient purchasing system and/or supply chain management system.^[@bibr19-0046958019887572][@bibr20-0046958019887572][@bibr21-0046958019887572]-[@bibr22-0046958019887572]^ The low availability of NCD medicines in the public sector is a common problem in many LMICs,^[@bibr19-0046958019887572],[@bibr20-0046958019887572],[@bibr22-0046958019887572]^ probably due to the lack of technical and economic resources required for the health system to deal with the double burden of communicable and noncommunicable disease.^[@bibr23-0046958019887572][@bibr24-0046958019887572]-[@bibr25-0046958019887572]^ The lower availability in the public sector needs more attention and the Ministry of Health needs to ensure these medicines are available to all. In Nepal, more than 60% of health care financing consists of out-of-pocket expenditure (for medicines, doctor visits, laboratory tests, transportation, and hospital stays).^[@bibr26-0046958019887572],[@bibr27-0046958019887572]^ Policy initiatives for universal health coverage and health sector reforms have been developed to improve health system efficiency, equity, and accessibility of health care for underprivileged groups,^[@bibr26-0046958019887572],[@bibr28-0046958019887572]^ but initiatives to improve the quality of health care services for patients at both private and public health facilities are still lacking.^[@bibr12-0046958019887572],[@bibr29-0046958019887572],[@bibr30-0046958019887572]^

The treatment of some selected NCD conditions and risk factors such as asthma, diabetes mellitus, hypertension, and hyperlipidemia costs less than a day's wage for a month of treatment when purchased medicines from private outlets. These 4 NCDs share 4 main behavioral risk factors (tobacco use, physical inactivity, unhealthy diet, and the harmful use of alcohol) leading to 4 key metabolic or physiological changes (raised blood pressure, overweight/obesity, raised blood glucose, and raised cholesterol).^[@bibr31-0046958019887572],[@bibr32-0046958019887572]^ Hence, a patient with 1 NCD may be prone to having other NCD conditions.^[@bibr31-0046958019887572],[@bibr33-0046958019887572],[@bibr34-0046958019887572]^ Such multiple morbidities may lead a patient to spend several days' wage for treatment. The minimum daily wage for an unskilled government worker was 265 NPR per day at the time of the survey.^[@bibr1-0046958019887572]^ However, many people will earn much less than that, so the actual cost of treatment of NCDs is more than the day's wage equivalent shown in our survey.

New policies or a change in existing policies may improve the availability and affordability of NCD medicines in public and private sectors. Improved governance and management efficiency, and a realistic assessment of local supply options could increase the availability in the public sector. Strategies to ensure adequate funds to purchase essential medicines in the public sector include sufficient and sustainable financing through national and international sources, pooling procurement, and other arrangements to improve purchasing efficiency and a sound supply chain management system.^[@bibr11-0046958019887572],[@bibr19-0046958019887572],[@bibr21-0046958019887572]^ Eliminating taxes and tariffs and regulating mark-up charges are initiatives that can reduce the price of NCD medicines in the private sector.^[@bibr11-0046958019887572],[@bibr19-0046958019887572]^ In Nepal, medicines are exempt from value-added tax and central government tax. Other policies are required to improve access to NCD medicines, eg, regulating the price of medicines, promoting generic medicines use, and implementing standard treatment guidelines.^[@bibr8-0046958019887572],[@bibr19-0046958019887572],[@bibr30-0046958019887572],[@bibr35-0046958019887572][@bibr36-0046958019887572]-[@bibr37-0046958019887572]^ Furthermore, there is a need to educate health professionals in the use of standard treatment guidelines which take into account price and affordability and encourage generic prescribing. Consumers need to be made aware of the availability, affordability, and acceptability of generic versus branded products. Promoting the use of generic medicines, price capping of essential medicines rather than allowing unregulated mark-ups; promoting rational use of medicines can be a way to address this problem.^[@bibr35-0046958019887572],[@bibr36-0046958019887572],[@bibr38-0046958019887572]^

In this study, medicines to treat cancer were omitted because our survey was mainly based on the WHO Package for Noncommunicable Diseases Interventions for Primary Health Care, which did not have cancer medicine.^[@bibr15-0046958019887572]^ Incor-porating cancer medicines was also technically an issue as most of the cancer medicines are not sold in most private pharmacies and are not available in primary care level public health care organizations. The results are limited, similar to all the studies adopting this method, because medicine outlets surveyed were not more than a day travel from a major urban area; data may be subject to external effects, such as market fluctuations and delivery schedules, and there were unavailable or missing, or both data. Furthermore, the study was not able to capture data about the medicines obtained through informal channels, such as street vendors. Nonetheless, the results highlight priority areas for action by the Ministry of Health and other stakeholders involved in improving access to medicines to improve the access issues related with NCDs. Series of consultations among the different stakeholders (eg, government, supply chain management system authority, pharmaceutical industries, importers, wholesalers, and retail pharmacies) may provide framework to work together to improve access to affordable medicines for NCDs.

Conclusion {#section12-0046958019887572}
==========

Patients with NCDs require a reliable supply of affordable medicines. This survey revealed that the essential medicines tend to be affordable in Nepal, but availability requires improvement, especially in the government facilities that cater for the poor. The article also discussed a range of policy and technical options which exist for governments to ensure that medicines for chronic diseases are consistently available and affordable.
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